Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy

International Journal of STD and AIDS

Volumn 17, Issue 4, 2006, Pages 237-246

  Lehtinen, M ^a,h   Idanpaan Heikkila I ^b   Lunnas, T ^c   Palmroth, J ^d   Barr, E ^e   Cacciatore, R ^f   Isaksson, R ^g   Kekki, M ^g   Koskela, P ^h   Kosunen, E ^a   Kuortti, M ^a   Lahti, L ⁱ   Liljamo, T ^a   Luostarinen, T ^j   Apter, D ^f   Pukkala, E ⁱ   Paavonen, J ^g  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b MERCK ANIMAL HEALTH   (United States)

^c Health Center of Turku   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Vaestoliitto   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

ⁱ Oulu Municipal Health Center   (Finland)

^j FINNISH CANCER REGISTRY   (Finland)

more..

Author keywords

Cervical cancer; Herd immunity; Prevention; Vaccination

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POPULATION; PRIORITY JOURNAL; QUESTIONNAIRE; REGISTER; SAMPLE SIZE; UTERINE CERVIX CARCINOMA; VIRUS PARTICLE;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; CLINICAL TRIALS, PHASE III; COHORT STUDIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MULTICENTER STUDIES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT SELECTION; POPULATION SURVEILLANCE; QUESTIONNAIRES; REGISTRIES; SEXUALLY TRANSMITTED DISEASES; VIRAL VACCINES;

EID: 33645538848     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206776253453     Document Type: Article

References (40)

1. Munoz N, Bosch XF, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27
2. Parkin D, Pisani P, Ferlay J. Estimates of the world incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41
3. Lehtinen M, Paavonen J. Effectiveness of human papillomavirus vaccination. Int J STD AIDS 2003;14:787-92
4. Laukkanen P, Koskela P, Pukkala E, et al. Time trends of HPV6/11 and HPV16 infection incidences in Finland. J Gen Virol 2003;84:2105-9
5. Anttila A, Pukkala E, Kallio M, et al. Effect of organized screening on cervical cancer incidence and mortality in Finland. Int J Cancer 1999;83:59-65
6. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400
7. Lehtinen M, Luukkaala T, Wallin KL, et al. Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. A meta-analysis. J Clin Virol 2001;22:117-124
8. Laukkanen P, Koskela P, Läärä E, Pukkala E, Lehtinen M. Risk of cervical neoplasia following incident human papillomavirus and associated population atributable fraction. A case-cohort study. Abstract 61. HPV Vaccines and Immunotherapies. Cambridge: Cambridge University Press, 2003
9. Dillner J, Knekt P, Schiller J, Hakulinen T. Prospective seroepidemiological evidence that HPV16 infection is a risk factor for esophageal squamous cell carcinoma. BMJ 1995;311:1346
10. Bjorge T, Dillner J, Anttila T. et al. Prospective seroepidemiological study of the role of human papillomavirus in non-cervical anogenital cancers. BMJ 1997;315:646-9
11. Bjorge T, Engeland A, Luostarinen T, et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 2002;87:61-4
12. Mork J, Lie AK, Glattre E, et al. A prospective study human papillomavirus infection as a risk factor for head and neck carcinomas. N Engl J Med 2001;344:1125-32
13. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51
14. Harper DM, Franco EL, Wheeler CM, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65
15. Myers ER, McCrory DC, Nanda K, Bastian L, Marchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71
16. Lehtinen M, Kibur M, Luostarinen T, et al. Prospects for phase II-IV HPV vaccination trials in the Nordic countries. J Clin Virol 2000;19:113-22
17. Pukkala E, Söderman B, Okeanov A, et al. Cancer Atlas of Northern Europe Cancer Society of Finland Publications 62. Helsinki: Cancer Society of Finland, 2001
18. Hakama M, Hristova L. Effect of screening for cancer in the Nordic countries. Acta Oncol 1998;36:1-60
19. Juni P, Altman D, Egger M. Assessing quality of clinical trials. BMJ 2001;323:442-6
20. Lehtinen M. Efficacy of HPV vaccination against cervical carcinoma. A population based follow up study in progress. Abstarct 10. HPV Vaccines and Immunotherapies. Cambridge: Cambridge University Press, 2003
21. [www.cancerregistry.fi, 2005]
22. Koskela P, Bjorge T, Brunsvig A, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000;85:35-9
23. Dillner J. Prövning av HPV vaccine ger etiskt dilemma. Läkärtidningen 2003;43:3391-2
24. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical papillomavirus infection in women during the first sexual relationship. Br J Obstet Gynaecol 2002;109:442-6
25. Paavonen J, Halttunen M, Hansson BG, et al. Prerequisites for human papillomavirus vaccine trial: results of feasibility studies. J Clin Virol 2000;19:25-30
26. Halloran ME, Struchiner CJ, Longini IM. Study designs for evaluating different efficacy and effectiveness aspects of vaccination. Am J Epidemiol 1998;146:789-803
27. Kibur M, af Geijersstamm V, Pukkala E, et al. Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination. Sex Transm Infect 2000;76:13-17
28. Gudmundsdottir T, Tryggvadottir L, Allende M, Mast TC, Briem H, Sigurdsson K. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial. Acta Obstet Gynecol Scand 2003;82:345-50
29. Kahn JA, Rosenthal SI, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003;14:300-6
30. Kosunen E, Rimpel M, Liinamo A, Jokela J. Trends in adolescent sexual behaviour in Finland late 1990's. J Soc Med 2000;37:273-82
31. Auvinen E, Niemi M, Malm C, Trontti A, Lehtinen M, Paavonen J. Joka kolmannella opiskelijalla papilloomavirusinfektio (in Finnish). Suomen Lääkäril 2004;59:1487-9
32. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Contr Clin Trial 2003;24:182-99
33. Brener ND, Collins JL, Kann L, Warren CW, Williams BI. Reliability of the youth risk behaviour survey questionnaire. Am J Epidemiol 1995;141:575-80
34. Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002;325:369-72
35. Lehtinen M, Paavonen J. HPV vaccination shows great promise. Lancet 2004;364:1731-2
36. Garnett G, Waddell H. Public health paradoxes and the epidemiology of human papillomavirus vaccination. J Clin Virol 2000;19:101-12
37. Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-62
38. Aasdsd D, Minutes of the FDA vaccine-related and Biologicals Advisory Committee: November 2001 [www.fda.gov.ohrms/dockets/ac/01/minutes/3805m1.pdf]
39. Lowy DR, Frazer IH. Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003;31:111-16
40. Haber M, Ndikuveze A. Estimation of individual and population vaccination effectiveness from time-to-event data. Stat Med 1998;17:2617-23